These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29946849)

  • 1. Cancer Susceptibility Genetic Testing in a High-Risk Cohort of Urban Ashkenazi Jewish Individuals.
    Nielsen SM; De Simone LM; Olopade OI
    J Genet Couns; 2018 Dec; 27(6):1405-1410. PubMed ID: 29946849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
    Cox DM; Nelson KL; Clytone M; Collins DL
    Mol Genet Genomic Med; 2018 Nov; 6(6):1236-1242. PubMed ID: 30152102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.
    Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
    JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
    Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
    Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999.
    Chodick G; Struewing JP; Ron E; Rutter JL; Iscovich J
    Eur J Med Genet; 2008; 51(2):141-7. PubMed ID: 18158280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
    Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
    Comen E; Davids M; Kirchhoff T; Hudis C; Offit K; Robson M
    Breast Cancer Res Treat; 2011 Aug; 129(1):185-90. PubMed ID: 21394499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed ≥50 years.
    Bernstein-Molho R; Shhada NA; Laitman Y; Netzer I; Shoval S; Friedman E
    Cancer; 2024 Aug; 130(16):2763-2769. PubMed ID: 38630906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    Tennen RI; Laskey SB; Koelsch BL; McIntyre MH; Tung JY
    Sci Rep; 2020 May; 10(1):7669. PubMed ID: 32376921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
    Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
    Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.
    Gal I; Gershoni Baruch R; Haber D; Dagan E; Eisenberg-Barzilai S; Zidan J; Friedman E
    Fam Cancer; 2004; 3(1):11-4. PubMed ID: 15131400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women.
    McClain MR; Nathanson KL; Palomaki GE; Haddow JE
    Genet Med; 2005 Jan; 7(1):34-9. PubMed ID: 15654226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.